The Short Version
The available evidence supports the main point that Hydrazine Capital was heavily concentrated in Y Combinator-backed companies. A credible published report gives the 75% figure directly, and other coverage is consistent with a strong YC focus. The main caveat is that the exact percentage appears to rest on a secondhand citation rather than primary fund records or repeated independent confirmation.